PEB - Pacific Edge Ltd

[Schrodinger]

"Abbott currently offers the only FDA-approved urine-based molecular test for bladder cancer, UroVysion, which is included in the National Comprehensive Cancer Network and European Association of Urology guidelines.

The FGFR3 mutation analysis assay will be available in early 2015. Abbott is also in the process of developing reagents for further studies, and is exploring collaborations with pharmaceutical companies to leverage the FGFR3 test as a companion diagnostic for emerging bladder cancer therapies."

Abbott only generates in excess of US$20 billion of sales a year - nothing compared to PEB.

Does the Abbott system do what PEB does in a different way?

[winner69]

Remember the Darling definition of successful commercialisation is 'getting a product to market'

Enduring sales and profitability is not part of that equation

I'm allowed to say that because not that long ago I put real cash into the business

[skid]

Soooooo....it was BFG who did some digging...before being banNEd--------I think we are going to call him ''Banned on the run''

[MAC]

Out of the shadows and into the light--do with it what you will
http://www.clpmag.com/2015/01/abbott...cer-biomarker/

Well done Skid you’ve highlighted the importance of game changing disruptive technologies, and Uroysion have done very well indeed to flip FGFR3 onto others right about now;

A contributing reason for them doing so will undoubtedly be the pending Pacific Edge study, presently underway, that will directly compare the performance of Uroyvision with Cxbladder.

As I understand, it is a very similar study to the one Pacific Edge conducted to demonstrate the superiority of Cxbladder over Alere’s NMP22. The results of this study are due quite soon as I’m aware.

One of the challenges for any prospective competitor is that they really do need to demonstrate a quantum leap in process detection. Especially in the very early stages of tumor detection where the big benefits lie for patients, where the bulk of tests are performed, and where the big prospective commercial gains are possible.

Most importantly are the Tis, Ta, T1, T2 and T3 early stages of cancer, these are the ones, where if detected, then your chances of recovery as a patient still remain prospective.

As one can see from the table we all know below, it is really very hard indeed for any competitor to compete with the 100% sensitivity that Pacific Edge offer, and clinicians may well choose a product with 100% sensitivity over one that is less accurate as lives are literally in their hands.

I think some really do under estimate just how competitive these Pacific Edge products really are likely to be and just what a leap they represent as a disruptive technology.

Good luck Abbot, you have bought an aging dog.

Attachment 7041

[skid]

Well done Skid you’ve highlighted the importance of game changing disruptive technologies, and Uroysion have done very well indeed to flip FGFR3 onto others right about now;

A contributing reason for them doing so will undoubtedly be the pending Pacific Edge study, presently underway, that will directly compare the performance of Uroyvision with Cxbladder.

As I understand, it is a very similar study to the one Pacific Edge conducted to demonstrate the superiority of Cxbladder over Alere’s NMP22. The results of this study are due quite soon as I’m aware.

One of the challenges for any prospective competitor is that they really do need to demonstrate a quantum leap in process detection. Especially in the very early stages of tumor detection where the big benefits lie for patients, where the bulk of tests are performed, and where the big prospective commercial gains are possible.

Most importantly are the Tis, Ta, T1, T2 and T3 early stages of cancer, these are the ones, where if detected, then your chances of recovery as a patient still remain prospective.

As one can see from the table we all know below, it is really very hard indeed for any competitor to compete with the 100% sensitivity that Pacific Edge offer, and clinicians may well choose a product with 100% sensitivity over one that is less accurate as lives are literally in their hands.

I think some really do under estimate just how competitive these Pacific Edge products really are likely to be and just what a leap they represent as a disruptive technology.

Good luck Abbot, you have bought an aging dog.

Attachment 7041

Was'nt really me --I just brought it into the light of day so was'nt guessing games any more
In this article it looks like they have a bit of a jump on most competitors if the second illustation is anything to go by--but of course CX is not on there so its obviuosly not the full picture
https://lsconnect.thomsonreuters.com...le-biomarkers/

PS-just because i have run with another outfit doesnt mean i dont wish any KIWI company well--Its damn frustrating they are not even included in the illustration.

[skid]

Was'nt really me --I just brought it into the light of day so was'nt guessing games any more
In this article it looks like they have a bit of a jump on most competitors if the second illustation is anything to go by--but of course CX is not on there so its obviuosly not the full picture
https://lsconnect.thomsonreuters.com...le-biomarkers/

PS-just because i have run with another outfit doesnt mean i dont wish any KIWI company well--Its damn frustrating they are not even included in the illustration.

Its just occurred to me that these examples are FDA approved--so it goes to show that while it may not be necessary--it is a good look,if no no other reason than to be included on the illustration

[biker]

Glad I made my money on PEB when it suddenly rocketed, which seems so long ago now, so I can view this thread, with its strutting ego's and cryptic innuendo as entertainment and with bemused interest.

Otherwise, why would you

(merriam-webster.com/dictionary/bemuse
to cause to have feelings of wry or tolerant amusement)

[Minerbarejet]

Abbott:

Activating FGFR3 gene mutations are seen in about 70% of low-grade and 15 to 20% of high-grade bladder cancer cases, making them useful biomarkers to assist in early detection.

Pacific Edge:

• Detected 100% of T1-T3, Tis and upper tract tumours.
• Detected 97% of high-grade tumours.
• Detected 68% of Ta tumours as compared to cytology at 35%.
• Distinguished between low grade Ta tumours and other detected urothelial carcinomas with a sensitivity of 91% and specificity of 90%

No comment

[Balance]

There have been some very good postings by the likes of Snapiti questioning and commenting on PEB's commercialization strategy, and why PEB is failing to get real sales traction out there.

Issue here is that the PEB bulls simply do not want to know.

A classic example is Snapiti questioning why at this stage of the sales and commercialization cycle is PEB resorting to user programs to try and convert urologists to use CxBladder. Is this really part of PEB's commercialization strategy from day 1 or is it a case of backtracking in the absence of sales? The evidence from PEB's presentations point towards a backtrack.

Meanwhile, PEB bulls think that other players with existing tests are sitting still?

The move by Abbott is an example of them upping their game to improve their test(s) and entrench their market position. Snapiti has alerted to others who are upping their game as well.

$14m left in PEB's bank as at 30 September 2014 to take on the likes of Abbott with their established product, distribution network and billions of dollars at their disposal.

Cash burn of $1m to $1.5m a month - will there be enough actual sales before the cash runs out? You can only provide free tests and support user programs for so long.

And it's not like PEB is racking in the cash from sales made - debtor level on the balance sheet is higher than sales!!!!!! First time I have seen such a situation many years of analysing balance sheets.

[Balance]

Hi Balance, that is your opinion and good for you I respect that. A lot of the posts that were put up in the frenzy are actually quite flawed and seriously lacking – talk about hype and exaggeration. However, I will concede one point and that has been highlighted to me throughout this tag team display; and, that is that the freight train could either have been Thomas or Percy, since my post I have researched and have downloaded images of both engines with passenger and freight rolling stock.

"Tens of thousands of tests" and the Chairman selling shares after that - that was the give away for me that PEB is not meeting sales target as far as my initial assessment was concerned.

Subsequent to that, there are obviously other information which reinforces my perception (concession to you - my perception).

Competitors, suppliers, customers etc - that's who I talk to besides the companies i analyse.